Under construction – not a live service
Sign in
Not yet taking people in TürkiyeNo phase

How GLP-1 diabetes and weight-loss medicines affect saliva and oral health

Follows saliva and teeth in people starting GLP-1 medicines for diabetes or obesity.

Key facts

Who runs it
Kırıkkale University
Where
Kirikkale, TürkiyeSee the site
Trial code
Registry title
Effects of GLP-1 Receptor Agonists on Saliva and Oral Health
Status
Not yet recruiting
People taking part
50 people, planned
Started
16 Oct 2026
Expected to end
15 Dec 2027
Type of study
Observational
Treatments tested
  • GLP-1 Receptor Agonists
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and/or obesity who are about to start a GLP-1 receptor agonist for the first time. It studies the effect on saliva and oral health.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes and/or obesity.
Earlier treatment
New GLP-1 receptor agonist prescription; never had GLP-1 receptor agonist treatment before.

Main reasons for not taking part

  • Sjögren's syndrome or known salivary gland disease
  • Past radiation therapy to the head and neck
  • Antibiotic or antifungal medicine in the last 3 months
  • Pregnancy, breastfeeding or current orthodontic treatment
  • Other severe systemic diseases or medicines that affect saliva flow

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Diagnosed with Type 2 Diabetes Mellitus and/or Obesity
  • Newly prescribed a GLP-1 receptor agonist and naive to GLP-1 receptor agonist therapy
  • Aged 18 to 65 years
  • Willing to provide saliva samples and complete study questionnaires

Who cannot take part

  • Use of antibiotic or antifungal medications within the last 3 months
  • Presence of Sjögren's syndrome or known salivary gland disease
  • History of radiation therapy to the head and neck region
  • Presence of other severe systemic diseases or use of medications that affect salivary flow
  • Pregnancy, lactation, or active orthodontic treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in Türkiye

  • Kirikkale University Faculty of DentistryKirikkale, TürkiyeContact: Merve Haberal, PhDNo longer taking part

About the trial

What the trial wants to find out

This study aims to evaluate the effects of GLP-1 receptor agonists (GLP-1RA) on salivary parameters and oral health in individuals who will use this medication for the first time due to a diagnosis of Type 2 diabetes and/or obesity. The research will be conducted with a longitudinal design including a total of 50 participants. Clinical examinations and saliva analyses will be performed at baseline (month 0), month 3, and month 6. The study will evaluate stimulated and unstimulated salivary flow rates, pH, and buffering capacity, as well as analyze antimicrobial peptide levels (sIgA and beta-defensin-3) and total protein. Participants' oral hygiene and caries activity will be measured using the Silness and Löe Plaque Index (PI), DMFT, and ICDAS-II indices. Additionally, dietary habits and subjective dry mouth symptoms will be monitored through questionnaires. The obtained data will be statistically analyzed by controlling for potential confounding factors such as HbA1c, BMI, CRP, and HOMA index.

The group in the trial

  • GLP-1 RA Group

    Patients diagnosed with Type 2 diabetes and/or obesity who are newly prescribed GLP-1 receptor agonists.

    Treatment: GLP-1 Receptor Agonists

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective Evaluation of the Effects of GLP-1 Receptor Agonists on Salivary Physicochemical Parameters, Antimicrobial Peptide Levels, and Oral Health
Plain-language title
How GLP-1 diabetes and weight-loss medicines affect saliva and oral healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07818226, who can take part
Record updated
14 September 2026